Micar Innovation (Micar21.com) listed in Deep Knowledge Analytics report: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2018 Q2 and 2018 Q4
This 100-page report marks the fourth installment in a series of reports on the topic of the Artificial Intelligence in Drug Discovery Industry that Deep Knowledge Analytics have been producing for more than 1 year now. We released the first edition of these reports, entitled “AI for Drug Discovery Landscape Overview 2017”, in the end of 2017, followed by “AI for Drug Discovery & Advanced R&D Q1 2018” in the first quarter of 2018, and “AI for Drug Discovery & Advanced R&D Q2 2018” in the second quarter of 2018.
The present edition consists of an updated overview of the state of the industry in Q2 of 2018, tuned to the latter half of 2018 and including extended coverage of major events in Q4 of 2018. It revisits the major insights, trends, data analytics, conclusions and forecasts of our previous report, analyzing which trends and conclusions are still on track, which ones have changed course, and which ones have been usurped by entirely new insights, trends and conclusions.
MICAR INNOVATION is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases. It focuses on non-clinical Proof-of-Concepts (POCs) in preclinical R&D and Hit-to-Lead (H2L) achievements in areas such as neuroscience, oncology, cardio-vascularity, dermatology, rare diseases. MICAR21 is their drug discovery platform for small molecule drug candidates. The business model is based on licensing their intellectual property to commercial partners and on the creation new spin out companies.Link to:AI for Advanced R&D and Drug Discovery Q4 2018 Link to:AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2018 / Q2